PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Hypogonadism: Therapeutic Risks, Benefits, and Outcomes.

Abstract Hypogonadism is a common condition defined by the presence of low serum testosterone levels and hypogonadal symptoms, and most commonly treated using testosterone therapy (TTh). The accuracy of diagnosis and appropriateness of treatment, along with proper follow-up, are increasingly important given the large increase in testosterone prescriptions and the recent concern for cardiovascular (CV) risk associated with TTh. In March of 2015, the US Food and Drug Administration required that testosterone product labels disclose a potential CV risk, despite the evidence base for this association being weak and inconclusive. However, TTh may improve CV outcomes rather than increase risks.
PMID
Related Publications

Late-life onset hypogonadism: a review.

Controversies in testosterone replacement therapy: testosterone and cardiovascular disease.

Risks of testosterone-replacement therapy and recommendations for monitoring.

Testosterone replacement therapy: who to evaluate, what to use, how to follow, and who is at risk?

Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.

Authors

Mayor MeshTerms
Keywords

Cardiovascular risk

Hypogonadism

Outcomes

Testosterone therapy

Journal Title the medical clinics of north america
Publication Year Start




PMID- 29406064
OWN - NLM
STAT- MEDLINE
DCOM- 20180208
LR  - 20180208
IS  - 1557-9859 (Electronic)
IS  - 0025-7125 (Linking)
VI  - 102
IP  - 2
DP  - 2018 Mar
TI  - Hypogonadism: Therapeutic Risks, Benefits, and Outcomes.
PG  - 361-372
LID - S0025-7125(17)30165-7 [pii]
LID - 10.1016/j.mcna.2017.10.011 [doi]
AB  - Hypogonadism is a common condition defined by the presence of low serum
      testosterone levels and hypogonadal symptoms, and most commonly treated using
      testosterone therapy (TTh). The accuracy of diagnosis and appropriateness of
      treatment, along with proper follow-up, are increasingly important given the
      large increase in testosterone prescriptions and the recent concern for
      cardiovascular (CV) risk associated with TTh. In March of 2015, the US Food and
      Drug Administration required that testosterone product labels disclose a
      potential CV risk, despite the evidence base for this association being weak and 
      inconclusive. However, TTh may improve CV outcomes rather than increase risks.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Sigalos, John T
AU  - Sigalos JT
AD  - Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.
FAU - Pastuszak, Alexander W
AU  - Pastuszak AW
AD  - Center for Reproductive Medicine, Baylor College of Medicine, 1 Baylor Plaza,
      Room N730 Houston, TX 77030, USA; Scott Department of Urology, Baylor College of 
      Medicine, 7200 Cambridge Street, Houston, TX 77030, USA.
FAU - Khera, Mohit
AU  - Khera M
AD  - Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge Street,
      Houston, TX 77030, USA. Electronic address: [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171206
PL  - United States
TA  - Med Clin North Am
JT  - The Medical clinics of North America
JID - 2985236R
RN  - 3XMK78S47O (Testosterone)
SB  - AIM
SB  - IM
MH  - Cardiovascular Diseases/chemically induced/etiology
MH  - Hormone Replacement Therapy/adverse effects
MH  - Humans
MH  - Hypogonadism/diagnosis/*drug therapy
MH  - Male
MH  - Risk Assessment
MH  - Risk Factors
MH  - Testosterone/*deficiency/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cardiovascular risk
OT  - Hypogonadism
OT  - Outcomes
OT  - Testosterone therapy
EDAT- 2018/02/07 06:00
MHDA- 2018/02/09 06:00
CRDT- 2018/02/07 06:00
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2018/02/09 06:00 [medline]
AID - S0025-7125(17)30165-7 [pii]
AID - 10.1016/j.mcna.2017.10.011 [doi]
PST - ppublish
SO  - Med Clin North Am. 2018 Mar;102(2):361-372. doi: 10.1016/j.mcna.2017.10.011. Epub
      2017 Dec 6.